Tiger Brokers

Ascendis Pharma held annual general meeting with 90.16% of shares voted

Reuters
Mar 25
Ascendis Pharma held annual general meeting with 90.16% of shares voted
  • Ascendis held its annual general meeting on March 23, 2026.
  • Lars Lüthjohan was elected chairman of the meeting.
  • Shareholders approved the audited annual report and discharged the board and management from liability.
  • A resolution to carry forward the consolidated loss of EUR 228 million through recognition in accumulated deficit was approved.
  • Board members were re-elected and Jean-Jacques Bienaimé was elected as a new non-executive board member, Deloitte was re-elected as auditor, and an authorization for the board to purchase up to nominal DKK 1,000,000 of shares or equivalent ADSs as treasury shares was approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-121795), on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10